Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
KRAS G12C mutation
KRAS mutation
Lung cancer
Non-small cell lung cancer
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
05
2020
revised:
21
06
2020
accepted:
24
06
2020
pubmed:
4
7
2020
medline:
22
6
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
KRAS mutations are found in 20-30 % of non-small cell lung cancers (NSCLC) and were traditionally considered undruggable. KRAS Patients enrolled in the prospective Thoracic Malignancies Cohort (TMC) between July 2012 to October 2019 with recurrent/metastatic non-squamous NSCLC, available KRAS results, and without EGFR/ALK/ROS1 gene aberrations, were selected. Data was extracted from TMC and patient records. Clinicopathologic features, treatment and overall survival (OS) was compared for KRAS wildtype (KRAS Of 1386 NSCLC patients, 1040 were excluded: non-metastatic/recurrent (526); unknown KRAS status (356); ALK/EGFR/ROS1 positive (154); duplicate (4). Of 346 patients analysed, 144 (42 %) were KRAS Patients with KRAS
Sections du résumé
BACKGROUND
KRAS mutations are found in 20-30 % of non-small cell lung cancers (NSCLC) and were traditionally considered undruggable. KRAS
METHODS
Patients enrolled in the prospective Thoracic Malignancies Cohort (TMC) between July 2012 to October 2019 with recurrent/metastatic non-squamous NSCLC, available KRAS results, and without EGFR/ALK/ROS1 gene aberrations, were selected. Data was extracted from TMC and patient records. Clinicopathologic features, treatment and overall survival (OS) was compared for KRAS wildtype (KRAS
RESULTS
Of 1386 NSCLC patients, 1040 were excluded: non-metastatic/recurrent (526); unknown KRAS status (356); ALK/EGFR/ROS1 positive (154); duplicate (4). Of 346 patients analysed, 144 (42 %) were KRAS
CONCLUSION
Patients with KRAS
Identifiants
pubmed: 32619782
pii: S0169-5002(20)30504-3
doi: 10.1016/j.lungcan.2020.06.030
pii:
doi:
Substances chimiques
KRAS protein, human
0
Proto-Oncogene Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
310-317Informations de copyright
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest No conflict of interest for WC, FF, MA, AO, H-LW, MI. JD has served as a consultant for Beigene, Lilly, Eisai, Amgen and Biocon; and institution has received research funding from Roche, Lilly, AstraZeneca/MedImmune, Beigene, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Bionomics. BJS has served as a compensated consultant or received honorarium from Amgen, Loxo Oncology, Roche/Genentech, Pfizer, Novartis, AstraZeneca, Merck and Bristol Myers Squibb.